J & J to Acquire Rights to a Clinical-Stage Bispecific Antibody Targeting AD
Johnson & Johnson is set to acquire rights to NM26, a bi-specific antibody for the treatment of atopic dermatitis (AD), through an agreement with Numab Therapeutics to acquire its wholly owned subsidiary Yellow Jersey Therapeutics (YJT). NM26, which is ready to enter Phase 2 studies, targets interleukin (IL) -4R alpha subunit (IL-4Rα) and IL-31 to […]